Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2007
09/04/2007US7265220 Amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative
09/04/2007US7265186 Multi-arm block copolymers as drug delivery vehicles
09/04/2007US7265156 Medicinal association of a biguanine and a carrier, for example metformin and arginine
09/04/2007US7265155 Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
09/04/2007US7265154 Valproic acid and derivatives thereof as histone deacetylase inhibitors
09/04/2007US7265153 Administering an aliphatic acid compound
09/04/2007US7265152 Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases
09/04/2007US7265151 Treatment of neurotic disorders
09/04/2007US7265150 E.g., [(2S)-1-(1,2-dioxo-3,3-dimethylpentyl)-2-hydroxymethylpyrrolidine; (2S)-1-(1, 2-dioxo-3,3-dimethylpentyl)-2-pyrrolidinetetrazole; (2S)-1-(1,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidinecarbonitrile; and 2S)-1-(1,2-dioxo-3,3-dimethylpentyl)-2-aminocarbonyl piperidine
09/04/2007US7265149 Pyrazolylakoxy-substituted indoleacetic acid derivatives, e.g., {6-[2-methyl-5-(4-trifluoromethyl-phenyl)-2H-pyrazol-3-ylmethoxy]-indol-1-yl}-acetic acid; used for treatment and/or prevention of diseases modulated by PPAR delta and/or PPAR alpha agonists.
09/04/2007US7265148 Substituted pyrrole-indoles
09/04/2007US7265147 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
09/04/2007US7265146 Administering small molecule compounds, especially acids or esters, that inhibit the interaction between alpha 4 integrins and ligands MAdCAM and/or VCAM for treatment of chronic inflammatory diseases such as arthritis, asthma, multiple sclerosis, Chrohn's disease, ulcerative colitis, and hepatitis C
09/04/2007US7265145 Bone disorders; osteoporosis; Paget's disease
09/04/2007US7265144 Mixture with other active materials; controlling glucose metabolism
09/04/2007US7265143 C-4 substituted retinoids
09/04/2007US7265142 Materials and methods for the treatment of hypertension and angina
09/04/2007US7265140 E.g., ({[Acetyl({(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl}-methyl)amino]carbonyl}oxymethyl acetate; these compounds have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria
09/04/2007US7265139 RXR activating molecules
09/04/2007US7265138 inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis
09/04/2007US7265137 Phenylacetic acid derivative; hypoglycemic agents; antilipemic agents; anticholesterol agents; cardiovascular disorders
09/04/2007US7265136 Substituted stilbene compounds with vascular damaging activity
09/04/2007US7265135 Antihistamines; cognition activators; Alzheimer's disease; antiepileptic agents; eating disorders; motion sickness; psychological disorders
09/04/2007US7265134 Tyrosine kinase inhibitors
09/04/2007US7265133 Biphenylylaminocarbonyl-amino- or -oxypiperidine derivatives, e.g., biphenyl-2-ylcarbamic acid 1-[2-({4-[(4-hydroxybenzylamino)methyl]benzoyl}methylamino)ethyl]piperidin-4-yl ester; treating bronchodilation and COPD
09/04/2007US7265132 Peptidyl spiroheterocyclic, amidino and guanidino compounds; reversible inhibitors of the cysteine protease cathepsin S, K, F, L and B; useful in the treatment of autoimmune and other related diseases
09/04/2007US7265131 For therapy of disease-states associated with nuclear receptor activity
09/04/2007US7265130 anti-obestic activity; Neuropeptide Y antagonist
09/04/2007US7265129 Anti-infective biaryl compounds
09/04/2007US7265128 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
09/04/2007US7265127 Imidazo[1,2-a]pyridine derivatives, especially N-(2-(8-(3-aminocarbonyl-2-pyridyloxy)imidazo[1,2-a]pyrid-3-yl)-1,1-dimethylethyl)-3-(o-isoxazol-3-ylphenoxy)-2-hydroxypropylamine; treating type-2 diabetes and obesity
09/04/2007US7265126 2,8-Diazaspiro[4.5]decan-1-one derivatives, e.g., 4-Phenyl-8-(1-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one; activate NMDA receptors via Glyt-1 inhibition and are used to treat neurological and neuropsychiatric disorders, particularly schizophrenia, cognitive impairment and Alzheimer's disease
09/04/2007US7265125 4-Heteroaminoquinazoline derivatives,.e.g., 2-methyl-4-piperidin-1-yl-7-pyridin-3-yl-quinazoline; prophylaxis or treatment of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity.
09/04/2007US7265124 Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound
09/04/2007US7265123 Heterocyclic compounds
09/04/2007US7265122 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
09/04/2007US7265121 Chemical compounds
09/04/2007US7265120 Pyrazine derivatives and pharmaceutical use thereof
09/04/2007US7265119 For therapy of nicotine dependency
09/04/2007US7265118 Useful for the treatment of medical disorders such as inflammation, arteriolosclerosis and angiogenesis
09/04/2007US7265117 Contain a preservative ingredient consisting of a combination of polyquaternium-1 and boric acid, ophthalmic solution
09/04/2007US7265116 Attention deficit disorders; hyperactivity; post-trauma stress disorders; anxiolytic agents; obsessive compulsive disorders; analgesics; Parkinson's disease
09/04/2007US7265115 Central nervous system-active cholinergic ligands for neuronal nicotinic receptors; Controlling synaptic transmission; selectively controlling neurotransmitter release; a (halopyridazinyl)-3,8-diazabicyclo(3.2.1)octane
09/04/2007US7265114 Antiproliferative agents for smooth muscle cells; antiinflammatory agents for endothelial cells; restenosis, atherosclerosis
09/04/2007US7265113 Anticancer agents; antiinflammatory agents, for therapy of rheumatoid arthritis
09/04/2007US7265112 Small molecule modulators of hepatocyte growth factor (scatter factor) activity
09/04/2007US7265111 inhibitors of lipolysis, as cardioprotective agents or they may be of value in the therapy of diabetes
09/04/2007US7265110 Psychological disorders; antidepressants; anxiolytic agents; analgesics; antiinflammatory agents; central nervous system disorders
09/04/2007US7265109 Thiazole derivatives
09/04/2007US7265108 For example, 6-[2-[4-(2-fluorophenoxymethyl)piperidino]ethyl]-1H-pyrazin-2-one; therapeutic or prophylactic agent for diabetic neuralgia, HIV neuralgia, postherpetic neuralgia, nerve system disorders
09/04/2007US7265107 For therapy and prophylaxis of microbial infections
09/04/2007US7265106 Chromatography; separation of enantiomorphs
09/04/2007US7265105 Pyrrolobenzodiazepines
09/04/2007US7265104 Tetraazabenzo[e]azulene derivatives and analogs thereof
09/04/2007US7265103 For therapy of depression, anxiety and body weight disorders
09/04/2007US7265102 Substituted pyrazoles
09/04/2007US7265101 Administering a therapeutically effective amount of a formulation containing an extract product of a plant material of an Asciepias plant to an individual desirous of a suppressed appetite
09/04/2007US7265100 Separation of regioisomers of metal phthalocyanines
09/04/2007US7265099 Use of chemical chelators as reversal agents for drug-induced neuromuscular block
09/04/2007US7265098 Polyacid/polyalkylene oxide gels and methods for their delivery
09/04/2007US7265097 Delivering therapeutic formulation containing sulphated chitinous polymer as a primary carrier across a membrane that has limited permeability for therapeutic agent
09/04/2007US7265096 treat or prevent diseases or disorders such as cancer or viral infections
09/04/2007US7265095 Monoclonal antibody 3F1H10 neutralising VHSV (viral haemorrhagic septicaemia virus)
09/04/2007US7265094 For therapy of cystic fibrosis
09/04/2007US7265093 administering a transglutaminase inhibitor, particularly a compound with a 3-halo-dihydroisoxazole moiety or an analog of isatin, to attenuate gluten toxicity
09/04/2007US7264945 IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons
09/04/2007US7264937 Oxydecahydronaphthalene modulators of HM74
09/04/2007US7264923 Infected macrophage that is deficient in a STAT-1-dependent anti-viral pathway, an interferon receptor-dependent anti-viral pathway, and/or a double-stranded RNA-dependent serine/threonine protein kinase-dependent anti-viral pathway
09/04/2007US7264833 Witherferin A derivatives and analogs extracted from Withania somnifera; preferential COX-2 inhibitors with little or no COX-1 activity; anticarcinogenic agents
09/04/2007US7264832 Cyclooxygenase-2 inhibitory withanolide compositions and method
09/04/2007US7264831 Cyclooxygenase-2 inhibitory withanolide compositions and method
09/04/2007US7264825 Pharmaceutical preparation with retarding active ingredient release, method for its production and its use
09/04/2007US7264823 Medical adhesive and methods of tissue adhesion
09/04/2007US7264822 Conjugated drug-polymer coated stent
09/04/2007US7264819 Administering methioninase with antibiotics (pentamidine, trimethoprim and/or sulfamethoxazole); Pneumocystis carinii (P.carinii); kits
09/04/2007US7264814 wherein at least one non-essential gene for replication thereof is inactivated; side effect reduction
09/04/2007US7264813 Therapeutic uses of Dunaliella powder
09/04/2007US7264799 Administering to patient before or simultaneously with surgery at least one heparinase enzyme, wherein heparinase enzyme decreases localized inflammatory response in the tissue of the patient
09/04/2007US7264798 Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus
09/04/2007US7264629 Photodynamic therapy for the treatment of hair loss
09/04/2007CA2444554C Pharmaceutical compositions of amlodipine and atorvastatin
09/04/2007CA2409999C Optical polymer mixtures for gastric retentive tablets
09/04/2007CA2405429C Minoxidil-containing preparation
09/04/2007CA2397828C Compounds having hypolipidemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them
09/04/2007CA2374688C Composite laminate and process for producing it
09/04/2007CA2336194C 1-(aminoalkyl)-3-quinoxaline-2-one derivatives for the preparation of compounds having an antioxidant action
09/04/2007CA2329665C Treatment of depression and pharmaceutical preparations therefor
09/04/2007CA2304702C Oral compositions of levosimendan
09/04/2007CA2297911C Substituted 6-phenylphenanthridines
09/04/2007CA2283083C Use of 2,3,4,5-tetrahydro-1h-3-benzazepines for the manufacture of a pharmaceutical composition for the treatment of sleep disorders
09/04/2007CA2274063C Substituted pyrimidine compounds and their use
09/04/2007CA2272118C Ubiquinone-containing, non-alcoholic beverage
09/04/2007CA2269132C Compositions to control oral microbial oxidation-reduction (eh) levels
09/04/2007CA2258044C Muscarinic antagonists
09/04/2007CA2239174C Novel compounds with analgesic effect
09/04/2007CA2232450C Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole
09/04/2007CA2219311C 10,13,15-trioxatricyclo[9.2.1.1.9.6]-pentadecanone derivatives, method for their production and pharmaceutical compositions containing them
09/04/2007CA2215329C Colorectal chemoprotective composition and method for preventing colorectal cancer
09/04/2007CA2181033C Use of n-alkyl derivatives of 1,5-dideoxy-1,5-imino-d-glucitol for the treatment of hepatitis b virus infections
09/04/2007CA2134479C Laser treatment